The Second Affiliated Hospital Zhejiang University School of Medicine

TUESDAY, Sept. 3, 2024 -- Four weeks of low-frequency repeated transcranial magnetic stimulation (rTMS) positively impacts poststroke urinary incontinence, according to a study published online Aug. 8 in Scientific Reports . Jialu Chen, from the Second Affiliated Hospital of Chongqing Medical University in China, and colleagues investigated the therapeutic effect of low-frequency rTMS on the contralesional primary motor cortex (M1) in 100 patients with poststroke urinary incontinence. The analysis included patients randomly assigned to the rTMS group or a sham-rTMS group. The researchers found that after four weeks of intervention, the maximum cystometric capacity, maximum detrusor pressure, residual urine output, overactive bladder score (including frequency, urgency, and urgency urinary incontinence), and the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form improved significantly in the rTMS group versus the sham-rTMS group. No changes in pelvic floor muscle electromyography were detected in patients in either group. "Future clinical experiments aimed at determining the effectiveness of rTMS for poststroke urinary incontinence patients should be based on the timing and degree of damage, which could result in more effective rTMS programs," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

SHANGHAI, China, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the successful completion of two randomized, double-blind, placebo-controlled, multi-center phase III clinical studies (Study nos.: JS002-003 and JS002-006) evaluating the company’s product ongericimab (a recombinant humanized anti-PCSK9 monoclonal antibody, product code: JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, and both studies have met their primary endpoints. According to the Report on Cardiovascular Health and Diseases in China (2021), in recent years, both the blood lipid levels and the prevalence of dyslipidemia of the Chinese population have been on the rise, and dyslipidemia affects up to 40.4% of adults. Dyslipidemia, specifically the increase of low-density lipoprotein cholesterol (“LDL-C”), is the most important independent risk factor for atherosclerotic cardiovascular diseases (“ASCVDs”). The growing prevalence of dyslipidemia underscores the urgent need for effective treatments to lower LDL-C levels, which can significantly lower the incidence of ASCVDs and the risk of death. At present, the awareness, treatment, and control rates of dyslipidemia in adults in China are all relatively low. The current lipid-lowering treatment and compliance rates among individuals at high or extremely high risk of ASCVDs are concerning, and there remains a relatively significant unmet clinical demand for lipid-lowering treatments. As a new lipid-lowering drug that effectively reduces LDL-C levels, PCSK9 inhibitors have been recommended in both Chinese and overseas dyslipidemia management guidelines, and are widely recognized by clinicians. Unfortunately, there are only two imported ant-PCSK9 monoclonal antibodies currently approved for marketing in China, and no domestic anti-PCSK9 monoclonal antibody has been approved for marketing. Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by Junshi Biosciences. Two major pivotal registered clinical studies (Study nos.: JS002-003 and JS002-006) of ongericimab have been successfully completed and met their primary endpoints. The JS002-003 study assessed the effectiveness and safety of subcutaneous injection of ongericimab for the treatment of patients with primary hypercholesterolemia and mixed dyslipidemia, while the JS002-006 study assessed the effectiveness and safety of subcutaneous injection using two drug delivery systems (pre-filled syringes and pre-filled automatic syringes) of ongericimab for the same indications. Ongericimab exhibited significant lipid-lowering efficacy in both studies with good safety. “The emergence of PCSK9 inhibitors has provided better treatment options for dyslipidemia patients, particularly those at high or extremely risk of ASCVD,” said Academician Yaling HAN from the General Hospital of Northern Theatre Command. “The positive results of ongericimab’s phase III clinical trials are very encouraging and show comparable efficacy and safety to similar PCSK9 inhibitors from overseas. We look forward to the launch of ongericimab to address unmet medical needs, and we hope the incidence and mortality of cardiovascular disease could decrease in China.” “I’m pleased to see a Chinese-developed anti-PCSK9 monoclonal antibody delivering such outstanding lipid-lowering outcomes,” said Professor Shuiping ZHAO from the Second Xiangya Hospital of Central South University. “This will equip our clinicians with more lipid-lowering treatment options and benefit countless patients in China. The management of the Chinese population’s blood lipid levels requires continuous improvement, and we expect ongericimab to contribute greatly to this process.” “I’m excited to witness the simultaneous success of two phase III studies examining ongericimab,” said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. “These achievements were only possible through the joint efforts and dedication of researchers, patients, and R&D teams. With China entering an aging society, we hope that ongericimab can provide additional treatment options for hyperlipidemia patients and address unmet medical needs.” About Ongericimab (JS002) Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by Junshi Biosciences for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. Junshi Biosciences is the first company in China to obtain clinical trial approval for the target drug. The company has completed Phase III clinical studies in patients with primary hypercholesterolemia and mixed hyperlipidemia, and Phase II clinical studies in patients with homozygous familial hypercholesterolemia. The enrollment of patients for Phase III clinical studies of heterozygous familial hypercholesterolemia has been completed. About Junshi BiosciencesFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic. Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com. Junshi Biosciences Contact InformationIR Team:Junshi Biosciencesinfo@junshipharma.com+ 86 021-6105 8800 PR Team:Junshi BiosciencesZhi Lizhi_li@junshipharma.com+ 86 021-6105 8800

Aug. 9, 2022 11:00 UTC PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2022. Second Quarter Results and Highlights AdaptHealth delivered net revenue and Adjusted EBITDA for the second quarter consistent with internal expectations, as it continues to overcome challenges resulting from industry shortages of CPAP equipment. Net revenue was $727.6 million compared to $617.0 million in the second quarter of 2021, an increase of 17.9%. Net income attributable to AdaptHealth Corp. was $14.0 million, or $0.09 per diluted share, compared to $79.1 million, or $0.12 per diluted share, in the second quarter of 2021. Non-acquired net revenue for the second quarter declined 0.3%. Sleep categories showed strong sequential growth, as the supply of PAP machines continues to improve relative to recent quarters. Adjusted EBITDA was $150.0 million, compared to $147.4 million in the second quarter of 2021, an increase of 1.8%. On a sequential basis, Adjusted EBITDA margin increased 110 basis points to 20.6%, as the Company continues to manage well through the inflationary environment and supply chain challenges. During the quarter, the Company completed four acquisitions, all of which were previously announced, bringing the year-to-date total to six acquisitions of HME and Sleep providers. Cash flow from operations was $103.5 million, compared to $129.2 million in the second quarter of 2021. The Company repurchased $3.4 million of its common stock in the open market during the quarter using available cash, pursuant to the previously-announced share repurchase authorization. Guidance Maintained for Fiscal Year 2022 The Company is maintaining its previously issued financial guidance for fiscal year 2022, as follows: Net revenue of $2.840 billion to $3.040 billion; Adjusted EBITDA of $615 million to $675 million; and Total capital expenditures representing 9-11% of net revenue. Guidance for fiscal year 2022 does not include any contribution from acquisitions that have not yet closed, or continuing Public Health Emergency benefits beyond the currently scheduled expiration date. Management Commentary Steve Griggs, Chief Executive Officer, commented, “We are very pleased with our performance through the first half of the year. During the quarter we have seen continued resilience in our HME and Sleep product lines as CPAP patient set ups remain at or near record levels resulting in rental census up 16% from February levels, and our diabetes product line continues to post double-digit growth. AdaptHealth continues to meet expectations for growth and profitability, and drive operating leverage even in the face of considerable inflation, fuel, freight, and labor market pressures. Our performance and results continue to demonstrate the crucial role we play in the lives of our approximately 3.9 million patients across the U.S. as a leading national provider of medical equipment, supplies, and services.” Josh Parnes, President, commented, “AdaptHealth continues to make important investments in technology throughout the organization that will drive improved operating performance, lower cost of care, and better outcomes for patients. As our results and expectations demonstrate, these investments are leading to increased efficiencies to help offset challenges in the operating environment, and adding value for shareholders as well as the broader healthcare continuum. We will continue to pursue arrangements to make home health easier for payors, patients, and providers, and believe we can gain share and volume within the industry.” Conference Call Management will host a conference call at 8:30 am ET today to discuss the results and business activities. Interested parties may participate in the call by dialing: (877) 407-6176 (Domestic) or (201) 689-8451 (International) Webcast registration: Click here Following the live call, a replay will be available for six months on the Company's website, under "Investor Relations." About AdaptHealth Corp. AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt to challenges in their activities of daily living, and thrive. Product and service offerings include (i) sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea, (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) HME to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 3.9 million patients annually in all 50 states through its network of over 750 locations in 47 states. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company’s acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company’s customers’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; and the impact of the coronavirus (COVID-19) pandemic and the Company’s response to it. A further description of such risks and uncertainties can be found in the Company’s filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Use of Non-GAAP Financial Information and Financial Guidance This release contains non-GAAP financial guidance, which is adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. The Company uses EBITDA and Adjusted EBITDA, which are financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures. The Company believes Adjusted EBITDA is useful to investors in evaluating the Company’s financial performance. The Company uses this metric as the profitability measure in its incentive compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most often used for purposes of contingent consideration arrangements. EBITDA and Adjusted EBITDA should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA and Adjusted EBITDA are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company’s liquidity. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items, including equity-based compensation expense, transaction costs, changes in fair value of the warrant liability, and other non-recurring items of expense or income in full year 2022. As a result, reconciliation of these non-GAAP measures to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. In addition, the Company’s non-GAAP financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and any specified items that have not yet been identified and quantified. The guidance also excludes macro-economic effects due to the COVID-19 pandemic that are not yet quantifiable. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. ADAPTHEALTH CORP. Condensed Consolidated Balance Sheets (Unaudited) (in thousands) June 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 118,809 $ 149,627 Accounts receivable 355,345 359,896 Inventory 102,675 123,095 Prepaid and other current assets 28,387 37,440 Total current assets 605,216 670,058 Equipment and other fixed assets, net 454,773 398,577 Operating lease right-of-use assets 135,748 147,760 Goodwill 3,515,612 3,512,567 Identifiable intangible assets, net 182,771 202,231 Other assets 15,674 15,098 Deferred tax assets 292,218 304,193 Total Assets $ 5,202,012 $ 5,250,484 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued expenses $ 314,973 $ 358,384 Current portion of finance lease obligations 4,347 15,446 Current portion of operating lease obligations 29,597 31,418 Current portion of long-term debt 25,000 20,000 Contract liabilities 31,411 31,370 Other liabilities 30,128 43,194 Total current liabilities 435,456 499,812 Long-term debt, less current portion 2,170,909 2,183,552 Operating lease obligations, less current portion 110,093 120,180 Other long-term liabilities 309,101 322,487 Warrant liability 38,760 57,764 Total Liabilities 3,064,319 3,183,795 Total Stockholders' Equity 2,137,693 2,066,689 Total Liabilities and Stockholders' Equity $ 5,202,012 $ 5,250,484 ADAPTHEALTH CORP. Consolidated Statements of Operations (Unaudited) Three Months Ended Six Months Ended (in thousands, except per share data) June 30, June 30, 2022 2021 2022 2021 Net revenue $ 727,614 $ 617,017 $ 1,433,817 $ 1,099,136 Costs and expenses: Cost of net revenue 610,011 490,720 1,207,133 887,418 General and administrative expenses 42,548 42,946 83,992 99,578 Depreciation and amortization, excluding patient equipment depreciation 15,877 17,944 31,962 31,324 Total costs and expenses 668,436 551,610 1,323,087 1,018,320 Operating income 59,178 65,407 110,730 80,816 Interest expense, net 25,608 23,147 50,384 45,332 Change in fair value of warrant liability 8,208 (37,454 ) (18,509 ) (40,622 ) Change in fair value of contingent consideration common shares liability — (22,079 ) — (24,044 ) Loss on extinguishment of debt — 7,736 — 11,949 Other loss, net 1,262 1,669 6,922 1,150 Income before income taxes 24,100 92,388 71,933 87,051 Income tax expense 8,853 12,330 14,456 10,635 Net income 15,247 80,058 57,477 76,416 Income attributable to noncontrolling interest 1,215 951 1,695 1,275 Net income attributable to AdaptHealth Corp. $ 14,032 $ 79,107 $ 55,782 $ 75,141 Weighted average common shares outstanding - basic 134,332 129,664 134,178 120,438 Weighted average common shares outstanding - diluted 137,015 136,582 138,335 127,720 Basic net income per share $ 0.10 $ 0.56 $ 0.38 $ 0.56 Diluted net income per share $ 0.09 $ 0.12 $ 0.24 $ 0.06 ADAPTHEALTH CORP. Consolidated Statements of Cash Flows (Unaudited) (in thousands) Six Months Ended June 30, 2022 2021 Cash flows from operating activities: Net income $ 57,477 $ 76,416 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization, including patient equipment depreciation 156,504 110,999 Equity-based compensation 11,222 16,029 Change in fair value of warrant liability (18,509 ) (40,622 ) Change in fair value of contingent consideration common shares liability — (24,044 ) Reduction in the carrying amount of operating lease right-of-use assets 9,530 15,368 Deferred income tax expense 11,975 6,544 Change in fair value of interest rate swaps, net of reclassification adjustment (1,460 ) (1,443 ) Amortization of deferred financing costs 2,617 2,306 Write-off of deferred financing costs — 3,495 Loss on extinguishment of debt from prepayment penalty — 8,454 Other (2,262 ) 428 Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable 7,027 (4,608 ) Inventory 18,807 15,841 Prepaid and other assets 10,406 8,678 Operating lease obligations (9,452 ) (15,016 ) Operating liabilities (83,958 ) (31,201 ) Net cash provided by operating activities 169,924 147,624 Cash flows from investing activities: Payments for business acquisitions, net of cash acquired (15,324 ) (1,292,631 ) Purchases of equipment and other fixed assets (154,340 ) (79,396 ) Payments for cost method investments (367 ) — Net cash used in investing activities (170,031 ) (1,372,027 ) Cash flows from financing activities: Proceeds from borrowings on long-term debt and lines of credit — 1,070,000 Repayments on long-term debt and lines of credit (10,000 ) (470,521 ) Repayments of finance lease obligations (12,547 ) (19,767 ) Payments for shares purchased under share repurchase program (3,375 ) — Proceeds from the exercise of stock options 723 2,300 Proceeds received in connection with employee stock purchase plan 753 314 Proceeds from the issuance of senior unsecured notes — 500,000 Proceeds from the issuance of Class A Common Stock — 278,850 Payments for equity issuance costs — (13,832 ) Payments of deferred financing costs — (18,039 ) Payments for tax withholdings from restricted stock vesting and stock option exercises (1,882 ) (810 ) Payments of contingent consideration and deferred purchase price from acquisitions (2,383 ) (16,341 ) Distributions to noncontrolling interests (2,000 ) (1,070 ) Payments for debt prepayment penalties — (8,454 ) Net cash (used in) provided by financing activities (30,711 ) 1,302,630 Net (decrease) increase in cash and cash equivalents (30,818 ) 78,227 Cash and cash equivalents at beginning of period 149,627 99,962 Cash and cash equivalents at end of period $ 118,809 $ 178,189 Non-GAAP Financial Measures This press release presents AdaptHealth’s EBITDA and Adjusted EBITDA for the three and six months ended June 30, 2022 and 2021. AdaptHealth defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization. AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus loss on extinguishment of debt, equity‑based compensation expense, transaction costs, change in fair value of the contingent consideration common shares liability, change in fair value of the warrant liability, and other non-recurring items of expense or income. The following unaudited table presents the reconciliation of net income (loss) attributable to AdaptHealth Corp. to EBITDA and Adjusted EBITDA for the three and six months ended June 30, 2022 and 2021: Three Months Ended Six Months Ended (in thousands) June 30, June 30, 2022 2021 2022 2021 Net income attributable to AdaptHealth Corp. $ 14,032 $ 79,107 $ 55,782 $ 75,141 Income attributable to noncontrolling interest 1,215 951 1,695 1,275 Interest expense, net 25,608 23,147 50,384 45,332 Income tax expense 8,853 12,330 14,456 10,635 Depreciation and amortization, including patient equipment depreciation 79,474 63,793 156,504 110,999 EBITDA 129,182 179,328 278,821 243,382 Loss on extinguishment of debt (a) — 7,736 — 11,949 Equity-based compensation expense (b) 5,720 7,447 11,222 16,029 Transaction costs (c) 2,205 8,100 5,313 39,954 Change in fair value of warrant liability (d) 8,208 (37,454 ) (18,509 ) (40,622 ) Change in fair value of contingent consideration common shares liability (e) — (22,079 ) — (24,044 ) Other non-recurring expense, net (f) 4,692 4,313 10,804 4,918 Adjusted EBITDA $ 150,007 $ 147,391 $ 287,651 $ 251,566 (a) Represents the write-off of unamortized deferred financing costs and other expenses related to refinancing of debt and pre-payment penalties for early debt payoff. (b) Represents equity-based compensation expense for awards granted to employees and non-employee directors. (c) Represents transaction costs and expenses related to integration efforts related to acquisitions. (d) Represents a non-cash charge or gain for the change in the estimated fair value of the warrant liability. (e) Represents a non-cash gain for the change in the estimated fair value of the contingent consideration common shares liability. (f) The 2022 year-to-date period consists of a $4.5 million expense related to changes in AdaptHealth’s estimated TRA liability, $3.6 million of expenses associated with litigation claims, $0.6 million of expenses associated with lease terminations, a $0.8 million loss related to the write-off of an investment, and $1.3 million of net other non-recurring expenses. The 2021 year-to-date period consists of $1.5 million of expenses related to legal and other costs associated with the separation of the Company’s former Co-CEO, $0.9 million of expenses associated with legal settlements for employee and other matters, $1.0 million of expenses associated with lease terminations, and $1.5 million of severance expense.